Drug pipelines rise or fall on decisions made with imperfect information, yet the signal hidden in clinical registries, regulatory filings, and conference disclosures has remained stubbornly hard to use at scale. That friction has distorted portfolio choices, delayed course corrections, and
Boardrooms demanded explainable AI long before chatbots charmed end users, and the gap between friendly prose and audited numbers left most pilots stranded in “demo limbo” where no one could sign off the results with confidence. Alteryx’s AI Insights Agent set out to close that gap by wiring Gemini
High‑end GPUs remained scarce, queue times stretched from hours to days, and model teams learned the hard way that single‑cloud loyalty often delayed launches more than it protected them from complexity. The case for cross‑cloud was not philosophical; it was practical—get access to capacity,
Two teams ask an AI agent for last quarter’s net revenue retention, receive two different numbers, and both results arrive stamped with confident explanations that sound right but do not agree. That is the moment dashboards stop being helpful, workflows stall, and trust in automation cracks—because
Stockswhipsawed, roadmapswerepaused, and designleadersfieldedpanickedpings as Claude Design’s preview ignited the market while leaving practitioners asking what actual work it could own. This roundup gathers perspectives from analysts, agency principals, enterprise buyers, and system integrators to
Trading models hungry for granular history stumble when petabytes live in sprawling CSV silos that burn cash with every scan and still miss deadlines because latency outruns decision cycles in live markets. That friction is why a quiet shift in file formats has become a headline story. Delta
